OBJECTIVE: To examine the effects of oral @entity172 /progestin on @entity322 and related lower urinary tract conditions among female nursing home (NH) residents. DESIGN: Randomized placebo-controlled trial. SETTING: Five NHs. @entity1 : Thirty-two incontinent female residents of average age 88. MEASUREMENTS: Subjects were randomized to receive either oral @entity172 (0.625 mg) combined with @entity1420 (2.5 mg) or placebo, daily for 6 months. Measures of @entity322 severity, the clinical appearance of the vagina, vaginal and urethral cytology, and urine and vaginal cultures were made at baseline, 3 months, and 6 months. In addition to active drug or placebo, all subjects received regular toileting assistance (prompted voiding) by trained research aides during 3-day data-collection periods to compensate for mobility and @entity73 . RESULTS: At 3 and 6 months there were no significant differences between the groups in the severity of @entity322 , the prevalence of @entity793 , or the results of vaginal cultures. Several clinical findings associated with @entity3941 improved more in the active than the placebo group and vaginal pH and vaginal and urethral cytology exhibited a partial estrogenic effect. CONCLUSIONS: Our results must be interpreted with caution because of the size and the select nature of our subject sample. Up to 6 months of oral @entity172 had only a partial estrogenic effect on vaginal and urethral epithelium and no clinical effects in this @entity1 population. We believe that future studies of @entity172 for @entity322 in frail NH residents should utilize a topical preparation and consider targeting @entity293 as an additional outcome measure.

Effects of oral XXXX and progestin on the lower urinary tract among female nursing home residents.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['patient', 'PARTICIPANTS'] @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence', 'incontinence'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairments'] @entity3941 :: ('MESH:D059268', 'Disease') :: ['atrophic vaginitis'] @entity793 :: ('MESH:D001437', 'Disease') :: ['bacteriuria'] @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection']
@entity172 :: (MESH:D004967,Chemical) :: ['estrogen']
